NASDAQ: XWELXwell Inc Stock
$1.80+0.38 (+26.76%)
Updated Apr 24, 2024
XWEL Price
$1.80
Fair Value Price
N/A
Market Cap
$7.53M
52 Week Low
$1.26
52 Week High
$6.40
P/E
-0.27x
P/B
0.58x
P/S
0.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$30.11M
Earnings
-$27.74M
Gross Margin
12.2%
Operating Margin
-92.02%
Profit Margin
-92.1%
Debt to Equity
1.39
Operating Cash Flow
-$16M
Beta
1.18
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
XWEL Overview
XWELL Inc., a health and wellness services company, provides spa services at airports. It operates through XpresSpa, XpresTest, Treat, and HyperPointe brands. The company offers spa services, including massage, and nail and skin care, as well as spa and travel products; and retail products. It also operates wellness centers that provides COVID-19 screening and testing, and rapid testing services for other communicable diseases, such as influenza, COVID-19, RSV, Flu A&B, and seasonal flu vaccination services; and other medical diagnostic testing services. In addition, the company offers services through an integrated digital platform, and a relevant retail offering to the traveling public. As of December 31, 2021, it operated 52 spa and clinic locations in 24 airports in the United States, the Netherlands, and the United Arab Emirates. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL Inc. in October 2022. XWELL Inc. is headquartered in New York, New York.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XWEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XWEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XWEL is good value based on its book value relative to its share price (0.58x), compared to the US Diagnostics & Research industry average (4.22x)
P/B vs Industry Valuation
XWEL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XWEL due diligence checks available for Premium users.
Be the first to know about important XWEL news, forecast changes, insider trades & much more!
XWEL News
Valuation
XWEL fair value
Fair Value of XWEL stock based on Discounted Cash Flow (DCF)
Price
$1.80
Fair Value
-$0.02
Undervalued by
11,972.54%
XWEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XWEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.27x
Industry
38.76x
Market
41.27x
XWEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
4.22x
XWEL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XWEL's financial health
Profit margin
Revenue
$7.4M
Net Income
-$6.6M
Profit Margin
-88.9%
XWEL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XWEL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$39.0M
Liabilities
$18.0M
Debt to equity
1.39
XWEL's short-term assets ($26.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XWEL's short-term assets ($26.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XWEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XWEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$6.8M
Financing
$0.0
XWEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XWEL vs Diagnostic & Research Stocks
Xwell Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.